Year archive

Gubra A/S — 2025 filings

All 20 regulatory filings released by Gubra A/S (GUBRA) in 2025, sourced directly from the official regulator.

20 Filings

2025 Period

2025 filings (20)

Filing	Released	Lang
Release_54869c99-e23f-4bfd-a380-50ad7ab3b310.pdf (English) Director's Dealing	2025-12-17	English
Boehringer Ingelheim advances next generation triple-agonist peptide for the treatment of obesity into mid-stage development Regulatory Filings	2025-12-08	English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares Director's Dealing	2025-11-10	English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares Regulatory Filings	2025-11-10	English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares Director's Dealing	2025-11-07	English
Record earnings for Gubra; revised outlook for the CRO business Earnings Release 9M 2025	2025-11-06	English
Interim report H1 2025: Group revenue and earnings record-high Interim / Quarterly Report H1 2025	2025-08-21	English
Interim report H1 2025: Group revenue and earnings record-high Interim / Quarterly Report H1 2025	2025-08-21	English
Record quarter for Gubra, but revised outlook for the CRO business Earnings Release Q2 2025	2025-08-20	English
Markus Rohrwild appointed new CEO of Gubra in a planned succession process Board/Management Information	2025-08-12	English
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares Director's Dealing	2025-07-10	Danish
Reporting of transactions made by persons discharging managerial responsibilities and persons closely associated with them in Gubra A/S' shares Director's Dealing	2025-07-10	Danish
Successful Transaction Closure of License Agreement Regulatory Filings	2025-04-01	English
Gubra announces positive GUBamy Phase 1 interim MAD results Regulatory Filings	2025-04-01	English
Regulatory Condition Satisfied for License Agreement between AbbVie and Gubra M&A Activity	2025-03-28	English
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity M&A Activity	2025-03-03	English
AbbVie and Gubra Announce License Agreement to Develop an Amylin Analog for the Treatment of Obesity Regulatory Filings	2025-03-03	English
Annual Report 2024: Excellent performance across Gubra Earnings Release FY 2024	2025-02-28	English
Annual Report 2024: Excellent performance across Gubra Annual Report FY 2024	2025-02-28	Danish
Annual Report 2024: Excellent performance across Gubra Annual Report FY 2024	2025-02-28	English